On May 2, the U.S. Food and Drug Administration and GlaxoSmithKline reminded health professionals not to use Promacta (eltromobopag) for the treatment of thrombocytopenia in patients with chronic liver disease. Read more at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm211796.htm.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder